Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Aug;40(8):1903–1909. doi: 10.1128/aac.40.8.1903

Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis.

D E Uehlinger 1, F Schaedeli 1, M Kinzig 1, F Sörgel 1, F J Frey 1
PMCID: PMC163437  PMID: 8843301

Abstract

The pharmacokinetic profile of fleroxacin was studied in eight noninfected patients receiving regular hemodialysis (four women and four men; mean age, 63 years; age range, 48 to 73 years). Dialysis clearances (mean +/- standard deviation) calculated from the amount of drug recovered in the dialysate exceeded those calculated from rates of extraction from plasma for fleroxacin (126 +/- 29 versus 73 +/- 11 ml/min) and its metabolite N-demethylfleroxacin (103 +/- 31 versus 72 +/- 15 ml/min) but not that for the metabolite fleroxacin N-oxide (100 +/- 25 versus 100 +/- 12 ml/min). Data were fitted to a two-compartment model over the total observation period of 8 days (six oral daily doses of 200 mg of fleroxacin on days 1 to 6 and hemodialysis treatments on day 1,3, and 6) by nonlinear mixed-effects modeling. The random variability of plasma fleroxacin concentrations was 13% about its prediction. The estimated metabolic clearance was 25 ml/min (coefficient of variation, 43%), and the calculated steady-state volume of distribution was 84 liters (coefficient of variation, 16%). The model was expanded for the two major metabolites by the addition of a two-compartment metabolite distribution. Formation clearances of N-demethylfleroxacin and fleroxacin N-oxide were estimated to be 54 and 33% of fleroxacin's metabolic clearance, respectively. The conclusions were as follows. Because of the slow metabolic clearance and intermittent dialysis treatment, steady-state conditions were not reached after 1 week of oral fleroxacin therapy, and there was relevant accumulation of fleroxacin as well as that of fleroxacin N-oxide in our patients with end-stage renal disease. We recommend that infected hemodialysis patients be treated with an initial oral dose of 400 mg of fleroxacin and then daily oral doses of 200 mg. One cannot recommend the treatment of this patient population with fleroxacin over prolonged time periods until more date about the levels of accumulation of fleroxacin and its metabolites in infected patients with renal disease are available.

Full Text

The Full Text of this article is available as a PDF (253.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bass O. E., Nolph K. D., Maher J. F. Dialysance and clearance measurements during clinical dialysis-a plea for standardization. J Lab Clin Med. 1975 Sep;86(3):378–385. [PubMed] [Google Scholar]
  2. Bertino J. S., Jr, Nafziger A. N., Wong M., Stragand L., Puleo C. Effect of a fat- and calcium-rich breakfast on pharmacokinetics of fleroxacin administered in single and multiple doses. Antimicrob Agents Chemother. 1994 Mar;38(3):499–503. doi: 10.1128/aac.38.3.499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fillastre J. P., Leroy A., Moulin B., Dhib M., Borsa-Lebas F., Humbert G. Pharmacokinetics of quinolones in renal insufficiency. J Antimicrob Chemother. 1990 Oct;26 (Suppl B):51–60. doi: 10.1093/jac/26.suppl_b.51. [DOI] [PubMed] [Google Scholar]
  4. Frey F. J., Gambertoglio J. G., Frey B. M., Benet L. Z., Amend W. J. Nonlinear plasma protein binding and haemodialysis clearance of prednisolone. Eur J Clin Pharmacol. 1982;23(1):65–74. doi: 10.1007/BF01061379. [DOI] [PubMed] [Google Scholar]
  5. Gibson T. P., Matusik E., Nelson L. D., Briggs W. A. Artificial kidneys and clearance calculations. Clin Pharmacol Ther. 1976 Dec;20(6):720–726. doi: 10.1002/cpt1976206720. [DOI] [PubMed] [Google Scholar]
  6. Greenwood R. N., Aldridge C., Goldstein L., Baker L. R., Cattell W. R. Assessment of arteriovenous fistulae from pressure and thermal dilution studies: clinical experience in forearm fistulae. Clin Nephrol. 1985 Apr;23(4):189–197. [PubMed] [Google Scholar]
  7. Hume R., Weyers E. Relationship between total body water and surface area in normal and obese subjects. J Clin Pathol. 1971 Apr;24(3):234–238. doi: 10.1136/jcp.24.3.234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Nakashima M., Kanamaru M., Uematsu T., Takiguchi A., Mizuno A., Itaya T., Kawahara F., Ooie T., Saito S., Uchida H. Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):133–144. doi: 10.1093/jac/22.supplement_d.133. [DOI] [PubMed] [Google Scholar]
  9. Nightingale C. H. Overview of the pharmacokinetics of fleroxacin. Am J Med. 1993 Mar 22;94(3A):38S–43S. [PubMed] [Google Scholar]
  10. Singlas E., Leroy A., Sultan E., Godin M., Moulin B., Taburet A. M., Dhib M., Fillastre J. P. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis. Clin Pharmacokinet. 1990 Jul;19(1):67–79. doi: 10.2165/00003088-199019010-00005. [DOI] [PubMed] [Google Scholar]
  11. Sorgel F., Metz R., Naber K., Seelmann R., Muth P. Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):155–167. doi: 10.1093/jac/22.supplement_d.155. [DOI] [PubMed] [Google Scholar]
  12. Stuck A. E., Frey F. J., Heizmann P., Brandt R., Weidekamm E. Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother. 1989 Mar;33(3):373–381. doi: 10.1128/aac.33.3.373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Stuck A. E., Kim D. K., Frey F. J. Fleroxacin clinical pharmacokinetics. Clin Pharmacokinet. 1992 Feb;22(2):116–131. doi: 10.2165/00003088-199222020-00003. [DOI] [PubMed] [Google Scholar]
  14. Sörgel F., Kinzig M. Pharmacokinetics of gyrase inhibitors, Part 1: Basic chemistry and gastrointestinal disposition. Am J Med. 1993 Mar 22;94(3A):44S–55S. [PubMed] [Google Scholar]
  15. Sörgel F., Kinzig M. Pharmacokinetics of gyrase inhibitors, Part 2: Renal and hepatic elimination pathways and drug interactions. Am J Med. 1993 Mar 22;94(3A):56S–69S. [PubMed] [Google Scholar]
  16. Taburet A. M., Devillers A., Thomare P., Fillastre J. P., Veyssier P., Singlas E. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients. Clin Pharmacokinet. 1990 Jul;19(1):80–88. doi: 10.2165/00003088-199019010-00006. [DOI] [PubMed] [Google Scholar]
  17. Weidekamm E. Pharmacokinetics of fleroxacin in renal impairment. Am J Med. 1993 Mar 22;94(3A):70S–74S. [PubMed] [Google Scholar]
  18. Weidekamm E., Portmann R., Partos C., Dell D. Single and multiple dose pharmacokinetics of fleroxacin. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):145–154. doi: 10.1093/jac/22.supplement_d.145. [DOI] [PubMed] [Google Scholar]
  19. Weidekamm E., Portmann R., Suter K., Partos C., Dell D., Lücker P. W. Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. Antimicrob Agents Chemother. 1987 Dec;31(12):1909–1914. doi: 10.1128/aac.31.12.1909. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES